Floatz logo

Veliparib

Renal Failure

National Cancer Institute (NCI)Small moleculePhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

19 Active assets in the Renal Failure cohort.

Asset / SponsorPhaseRating
NORMAL HUMAN SERUM ALBUMIN
Anna Cruceta
Phase 4BBB
Midodrine
Anna Cruceta
Phase 4BB
DEXAMETHASONE
Augusta University
Phase 3BB
Envarsus Product
University of Alberta
Phase 4BB
Empagliflozin
University Hospital, Basel, Switzerland
Phase 4BB

View all 50 →

Same molecule, other indications

Veliparib is also rated in:

non-small cell lung carcinomaDormant
BBB
Indicative ·
74 / 100
View asset →
Stage IV Pancreatic CancerDormant
BB
Indicative ·
71 / 100
View asset →
small cell lung carcinomaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →